Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group

Table 2 Key medications used globally in the management of MCL

Agent	Class	Availability in Asia
Cyclophosphamide	Alkylating agent	Widely available
Doxorubicin	Anthracycline	Widely available
Vincristine	Microtubule assembly blocker	Widely available
Cytarabine	DNA polymerase inhibitor	Cytarabine is the backbone of chemotherapy regimens in Asia
Cisplatin	DNA replication inhibitor	Widely available
Lenalidomide	Immunomodulatory agent	Approved and reimbursed in limited countries
Bendamustine	Alkylating agent	Approved and reimbursed excluding Korea
Rituximab	Monoclonal antibody	Approved and reimbursed as R-CHOP or R-HyperCVAD R-maintenance is limitedly available
Temsirolimus	mTOR inhibitor	Rarely used outside of Asia
Bortezomib	Proteasome inhibitor	Approved and reimbursed for first-line use as VR-CAP
Acalabrutinib	BTK inhibitor	Not available in Asia
Zanubrutinib	BTK inhibitor	Not available in Asia
Ibrutinib	BTK inhibitor	Widely approved and reimbursed for rrMCL
Venetoclax	BH3-mimetic	Approved for MCL in limited countries

BH3 B cell lymphoma 2 homology 3; BTK Bruton’s tyrosine kinase; MCL mantle cell lymphoma; mTOR mammalian target of rapamycin; R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; R-hyperVCAD rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone + methotrexate and high-dose cytarabine; rrMCL relapsed/refractory mantle cell lymphoma;VR-CAP bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone

ISSN: 1756-8722